Amy Burroughs to lead Cleave Therapeutics; Cynthia Collins clinches Editas CEO job amid historic CRISPR move
→ After bagging $12 million to advance its lead drug candidate CB-5339 — a (VCP)/p97 inhibitor — through early clinical development, …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
